Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 1,738 trials

AR Positive Triple-Negative Breast Cancer: Bicalutamide and Abemaciclib Study

We are studying a combination of bicalutamide and abemaciclib for patients with AR positive triple-negative breast cancer. The goal is to see if this treatment helps control the disease and to evaluate its safety.

Locally Advanced Unresectable or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Multiple Myeloma: TG01/QS-21 Vaccine Study

We are investigating a new vaccine for patients with specific genetic mutations in multiple myeloma. The study aims to evaluate its safety and effectiveness in those at high risk or with measurable disease.

Multiple MyelomaSafety phase (I)Efficacy phase (II)HematologyOncology

Recurrent Prostate Cancer: SpectraCure P18 System Study

We are evaluating a new treatment system using lasers and a drug for men with recurrent prostate cancer. The study aims to ensure safety and effectiveness in targeting and eliminating cancer cells.

Recurrent Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

B-cell Acute Lymphoblastic Leukemia: UCART22 Treatment Study

We are testing a new engineered T-cell therapy, UCART22, for patients with relapsed or refractory B-ALL. The study aims to evaluate its safety and effectiveness, especially for those who have not responded to other therapies.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Advanced Hepatobiliary Cancer: New Immunomodulators

We are studying new immunomodulators to see if they can improve treatment outcomes for patients with advanced hepatobiliary cancer. This includes testing their safety and effectiveness alone and with other cancer therapies.

Bile Duct CancerGallbladder CancerHepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Alpha-Thalassemia: Luspatercept Treatment Study

We are investigating whether Luspatercept can improve anemia in adults and adolescents with Alpha-thalassemia. The study will also assess the safety of this treatment in younger participants.

Alpha ThalassemiaEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteHematology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

THC Oil for Chronic Neuropathic Pain

We are studying the effects of THC 2% oil on pain relief in patients with chronic neuropathic pain. The trial will also explore how different patient traits may influence the treatment's effectiveness and safety.

Neuropathic Pain≤3 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteInternal MedicineNeurology

Breast Cancer Treatment: Tucatinib and Capecitabine

We are studying a combination of tucatinib, capecitabine, and trastuzumab for patients with HER2-positive breast cancer that has spread to the meninges. The goal is to see if this treatment improves survival and quality of life.

HER2-Amplified Metastatic Breast Cancer with Leptomeningeal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pancreatic Cancer: New Treatment Combination Study

We are studying a new treatment combining autogene cevumeran, atezolizumab, and mFOLFIRINOX for patients with resected pancreatic ductal adenocarcinoma. The goal is to see if this combination improves survival compared to standard mFOLFIRINOX alone.

Pancreatic Cancer>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessCost ReimbursementOncology

CAR-T-Cell Treatment for High-Risk Mantle Cell Lymphoma

We are exploring a new CAR-T-cell therapy for patients with untreated high-risk Mantle Cell Lymphoma. The study compares this new approach to the standard treatment to see which is more effective and safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Advanced Colorectal Cancer: Cetuximab with Encorafenib and Binimetinib

We are studying a combination of three medications for patients with BRAF V600E mutated advanced colorectal cancer. The goal is to see if this treatment can help make surgery possible and improve overall health outcomes.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Cutaneous T-Cell Lymphoma: Mogamulizumab and Skin Radiation Therapy

We are studying a new treatment combining an antibody and skin radiation for patients with stage IB-IIB cutaneous T-cell lymphoma. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Cutaneous T-cell LymphomaMycosis Fungoides and Sézary Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Advanced Breast Cancer: [177Lu]Lu-NeoB with Ribociclib and Fulvestrant

We are exploring a new treatment combination for patients with ER+, HER2-, and GRPR+ advanced breast cancer who have not responded to earlier therapies. The study aims to assess the safety and effectiveness of this approach.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)EndocrinologyOncology

Advanced Cutaneous Squamous Cell Carcinoma: INCB099280 Study

We are evaluating a new medication for people with advanced cutaneous squamous cell carcinoma to see how safe it is and if it may help improve their condition.

Recurrent and Metastatic Skin Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Acute Myeloid Leukemia: Gilteritinib vs. Midostaurin

We are studying whether gilteritinib works better than midostaurin for patients with AML or MDS with a FLT3 mutation. This trial looks at treatment effectiveness and safety during chemotherapy and maintenance therapy.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2)1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Methylmalonic Acidemia: mRNA-3705 Treatment Study

We are testing a new treatment, mRNA-3705, for individuals with isolated Methylmalonic Acidemia. The study aims to evaluate its safety and how well it lowers harmful acid levels in the blood.

Methylmalonic Aciduria>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Beta-Thalassemia: Luspatercept for Children

We are studying a new treatment called luspatercept for children with beta-thalassemia to find a safe dose and evaluate its effects on blood health. This trial includes both transfusion-dependent and non-transfusion-dependent participants.

Beta Thalassemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Nipocalimab for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to 17 with generalized myasthenia gravis who are not getting enough benefit from their current therapy. The trial will help us learn about its safety and effectiveness.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPediatrics

Multiple Sclerosis: BIIB091 Treatment Study

We are studying the safety of BIIB091 alone and with Diroximel Fumarate in adults with relapsing forms of multiple sclerosis. The goal is to see how these treatments affect brain inflammation.

Relapsing Multiple Sclerosis1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementNeurology